Ciba-geigy Corporation

Novartis Ag

Novartis Corporation

Novartis Finance Corporation

Alfred Sallmann

Pier G Ferrini

Gerhard Baschang

Andreas Beck

Ernst Habicht

Paul Wenk

Richard Goschke

Robert W Lang

Alberto Rossi

Rudolf Pfister

Marc Gerspacher

Niklaus Buhler

Hans H Bosshard

Eric Francotte

Gyorgy Lajos Kis

Alica Huxley

Hans-Peter Gschwind

Wolfgang Blum

Willy Meyer

Rolf Schurter

Georges Haas

Walter Riess

The present invention describes an ophthalmic composition comprising diclofenac potassium, the use of said composition as a medicament for treating inflammatory conditions of the eye, for treating glaucoma or for treating ear inflammatory and/or painful conditions (otitis); as well as the use of diclofenac potassium in the preparation of a pharmaceutical composition for treating any inflammatory condition of the eye, for treating glaucoma or for treating ear inflammatory and/or painful conditions (otitis).

Ophthalmic and aural compositions containing diclofenac potassium

Salts of 2-�(2,6-dichlorophenyl)amine!phenylacetoxyacetic acid with

Substituted oxazolidines

The present invention relates to novel oxazolidines of formula (1) ##STR1## wherein R.sub.1 and R.sub.2 are simultaneously hydrogen or both are the same lower alkyl radical or together are 4- to 7-membered lower alkylene, and to the salts thereof in racemic and chiral form, to the preparation of these novel compounds, to pharmaceutical compositions containing them and to the use thereof as medicaments. The compounds have a stimulating effect on beta-adrenergic receptors and can be used, inter alia, for the treatment of diseases associated with reversible obstruction of the respiratory tract, typically asthma and chronic bronchitis, and also for inflammations of different origin.

5-(3-formylamino-4-hydroxyphenyl)-3-(1-

The invention relates to a novel process for the preparation of compounds of formula I ##STR1## wherein R is straight-chain C.sub.2 -C.sub.4 alk-1-en-1-yl, and salts thereof, and to a novel starting material and the use thereof.

Process for the preparation of substituted indoles

The invention relates to compounds of formula I ##STR1## wherein R is hydrogen or C.sub.1 -C.sub.7 alkyl, or wherein R is the structural element-alk-R.sub.1 in which alk is C.sub.1 -C.sub.7 alkylene, C.sub.2 -C.sub.7 alkylidene or C.sub.3 -C.sub.6 cycloalkylidene and R.sub.1 is hydroxy, C.sub.1 -C.sub.7 alkoxy, phenyl-C.sub.1 -C.sub.7 alkoxy or C.sub.2 -C.sub.7 alkanoyloxy; in free form or in the form of a salt; processes for their preparation, their use, and also pharmaceutical compositions comprising a compound of formula I in free form or in the form of a pharmaceutically acceptable salt.

Acetylene compounds and pharmaceutical compositions and methods of using

The invention relates to the codeine salt of [2-[(2,6-dichlorophenyl)-amino]-phenyl]-acetic acid of formula ##STR1## to processes for the preparation thereof, to pharmaceutical compositions comprising that salt, and to its use as an analgesic drug. Compositions comprising the salt of formula I are used especially in the case of severe painful conditions.

Codeine salt of a substituted carboxylic acid, its use and

Novel trisubstituted indole compounds of formula ##STR1## wherein R is straight-chain C.sub.2 -C.sub.4 alk-1-en-1-yl, and their salts can be used as pharmaceutical active ingredients and can be manufactured in a manner known per se.

Substituted indoles

4-Acylresorcinol ethers of the formula ##STR1## in which R.sub.1 is lower alkyl, R.sub.2 is fluorinated lower alkyl, R.sub.3 is hydrogen, lower alkoxy, trifluoromethyl or halogen, alk is an alkylene or hydroxyalkylene radical which is uninterrupted or interrupted by oxygen, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 which differs from this is a radical R.sub.9 and a radical R.sub.7 which differs from this is a radical R.sub.10, R.sub.6 is hydrogen, lower alkyl, trifluoromethyl, halogen, carboxyl which is free, esterified or amidated, cyano or lower alkanoyl, R.sub.8 is carboxyl which is free, esterified or amidated or 5-tetrazolyl, R.sub.9 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl and R.sub.10 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or carboxyl which is free, esterified or amidated, and their salts have antiallergic and antiinflammatory properties.

Novel fluorinated resorcinol ethers and their use as anti-allergics and

Novel 4-acylresorcinol ethers of the formula ##STR1## in which R.sub.1 represents lower alkyl, R.sub.2 represents lower alkyl, lower alkenyl or lower alkynyl, R.sub.3 represents hydrogen, lower alkoxy, trifluoromethyl or halogen, alk represents an alkylene radical, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.9 and a radical R.sub.7 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.10, R.sub.6 represents hydrogen, lower alkyl, halogen, trifluoromethyl, optionally esterified or amidated carboxy, cyano or lower alkanoyl, R.sub.8 represents optionally esterified or amidated carboxy, or 5-tetrazolyl, R.sub.9 represents hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and R.sub.10 represents hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or optionally esterified or amidated carboxy, and their salts have LTD.sub.4 -antagonistic and PLA.sub.2 -phospholipase-inhibiting properties. They can be manufactured according to methods known per se.

Novel resorcinol ethers and anti-inflammatory and anti-allergic use

4-Acylresorcinol esthers of the formula ##STR1## in which R.sub.1 is lower alkyl, R.sub.2 is fluorinated lower alkyl, R.sub.3 is hydrogen, lower alkoxy, trifluoromethyl or halogen, alk is an alkylene or hydroxyalkylene radical which is uninterrupted or interrupted by oxygen, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 which differs from this is a radical R.sub.9 and a radical R.sub.7 which differs from this is a radical R.sub.10, R.sub.6 is hydrogen, lower alkyl, trifluoromethyl, halogen, carboxyl which is free, esterified or amidated, cyano or lower alkanoyl, R.sub.8 is carboxyl which is free, esterified or amidated or 5-tetrazolyl, R.sub.9 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl and R.sub.10 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or carboxyl which is free, esterified or amidated, and their salts have antiallergic and antiinflammatory properties. They are prepared, for example, by reacting compounds of the formulae ##STR2## in which one of the radicals X.sub.5 and X.sub.6 is hydroxyl which is free or in salt form and the other is an alkoxy radical substituted by reactive esterified hydroxy or epoxy. The invention also relates to intermediates of the formula ##STR3## in which R.sub.2 is fluorinated lower alkyl, R.sub.3 is hydrogen, lower alkoxy, trifluoromethyl or halogen and R.sub.11 is hydrogen or a group of the formula R.sub.1 --C(--O)--, in which R.sub.1 is lower alkyl, and their salts.

Oxaloamino substituted fluorinated resorcinol ethers and anti-allergic

Novel 4-acylresorcinol ethers of the formula ##STR1## in which R.sub.1 is lower alkyl, alk is a hydroxyalkylene radical which can be interrupted by oxygen and R.sub.2 is 5-tetrazolyl, it being possible for the ring A to be additionally substituted by a lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy and/or halogen and for the ring B to be additionally substituted by lower alkyl, lower alkanoyl, lower alkoxy, lower alkoxycarbonyl, carboxyl, cyano, carbamyl, halogen and/or trifluoromethyl, and salts thereof have antiallergic properties and can be used as active compounds for medicaments. They are prepared by methods known as per se.

N-(substituted phenyl) tetrazol-5-yl carboxamides and anti-allergic use

4-Acylresorcinol ethers of the formula ##STR1## in which R.sub.1 is lower alkyl, R.sub.2 is fluorinated lower alkyl, R.sub.3 is hydrogen, lower alkoxy, trifluoromethyl or halogen, alk is an alkylene or hydroxyalkylene radical which is uninterrupted or interrupted by oxygen, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 which differs from this is a radical R.sub.9 and a radical R.sub.7 which differs from this is a radical R.sub.10, R.sub.6 is hydrogen, lower alkyl, trifluoromethyl, halogen, carboxyl which is free, esterified or amidated, cyano or lower alkanoyl, R.sub.8 is carboxyl which is free, esterified or amidated or 5-tetrazolyl, R.sub.9 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl and R.sub.10 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or carboxyl which is free, esterified or amidated, and their salts have antiallergic and antiinflammatory properties. They are prepared, for example, by reacting compounds of the formulae ##STR2## in which one of the radicals X.sub.5 and X.sub.6 is hydroxyl which is free or in salt form and the other is an alkoxy radical substituted by reactive esterified hydroxyl or epoxy. The invention also relates to intermediates of the formula ##STR3## in which R.sub.2 is fluorinated lower alkyl, R.sub.3 is hydrogen, lower alkoxy, trifluoromethyl or halogen and R.sub.11 is hydrogen or a group of the formula R.sub.1 --O(.dbd.O)--, in which R.sub.1 is lower alkyl, and their salts.

Novel fluorinated resorcinol ethers

Quinolinone derivatives of the formula (I) ##STR1## in which X represents oxy or a direct bond, R.sub.1 represents an aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclic-aliphatic radical or hydrogen, Ph represents an optionally additionally substituted 1,2-phenylene radical containing the group R.sub.1 --X--C(O)--, and one of the radicals R.sub.2 and R.sub.3 represents an optionally esterified or amidated carboxy group R.sub.4 and the other represents hydrogen or an aliphatic radical or, in the case of a radical R.sub.3, hydroxy, and in which either R.sub.A and R.sub.B together represent oxo, R.sub.C and R.sub.D together represent an additional bond, or, when R.sub.2 represents a radical R.sub.4, R.sub.C is hydrogen and R.sub.3 and R.sub.D together represent oxo, and R.sub.E represents a radical R.sub.5 which represents hydrogen or an aliphatic, cycloaliphatic, araliphatic heterocyclic-aliphatic radical, or R.sub.A represents an optionally etherified hydroxy group and R.sub.B together with R.sub.C and also R.sub.D together with R.sub.E represent an additional bond in each case, or, when R.sub.2 represents a radical R.sub.4, R.sub.B and R.sub.C together represent an additional bond and R.sub.3 and R.sub.D together represent oxo and R.sub.E represents a radical R.sub.5, and their salts, have antiallergic properties. They are manufactured, for example, by subjecting a compound of the formula (IV) ##STR2## in which Z represents a removable radical, or a tautomer and/or salt thereof, to intramolecular cyclisation.

Growing community of inventors

Bottmingen, Switzerland

Alfred Sallmann